Results from The Neotorch trial: perioperative toripalimab plus chemotherapy versus chemotherapy alone for the treatment of resectable stage III NSCLC
In this medfyle
In the Neotorch phase 3 study, the addition of perioperative toripalimab to chemotherapy showed statistically significant and clinically meaningful improvement in event-free survival compared with chemotherapy alone in patients with resectable stage III NSCLC.
About this Medfyle
©2024 Medfyle. All rights reserved.
Original article:
Lu S, Zhang W, Wu L, Wang W, Zhang P; Neotorch Investigators; Fang W, Xing W, Chen Q, Yang L, Mei J, Tan L, Sun X, Xu S, Hu X, Yu G, Yu D, Yang N, Chen Y, Shan J, Xing L, Tian H, Zhang X, Zhou M, Fang H, Wu G, Liu Y, Ye M, Cao L, Jiang J, Li X, Zhu L, Li D, Kang M, Zhong A, Chen K, Wu N, Sun Q, Ma H, Cai K, Wang C, Lin G, Zhu K, Zhang Y, Zhang X, Hu H, Zhang W, Chen J, Yang Z, Hang X, Hu J, Huang Y, Zhang Z, Zhang L, Zhang L, Liu L, Lin D, Zhang J, Chen G, Li Y, Zhu L, Wang W, Yu W, Cao D, Keegan P, Yao S. Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. JAMA. 2024 Jan 16;331(3):201-211. doi: 10.1001/jama.2023.24735. PMID: 38227033; PMCID: PMC10792477.
The summary content was prepared by Rhian Shurlock for Medfyle, and reviewed by Marianna Aita, MD.
The authors of the original article and the publisher were not involved in the creation of the summary.
